The trial is randomized, double-blind and placebo-controlled and involves 18-year-old to 49-year-old healthy adult men and women.
Here are four points:
1. The researchers will use the study to examine the norovirus vaccine’s effect on moderate or severe acute gastroenteritis.
2.. Takeda’s Phase 1 and Phase 2 norovirus vaccine candidate studies showed humans tolerated the vaccine well. The vaccine also reduced disease symptoms and severity.
3. Takeda Pharmaceutical focuses on oncology, gastroenterology and central nervous system therapeutic areas.
4. Norovirus is the main cause of acute gastroenteritis, causing nearly 700 million cases worldwide and more than 200,000 deaths per year.
More articles on GI & endoscopy:
4 things to know about Healthmark’s Endoscope Cleaning Brush
5 most read GI/endoscopy stories: June 13 — June 17
Ohio Gastroenterology & Liver Institute incorporates HyGIeaCare Prep System: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
